These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9521401)

  • 1. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery.
    Ward B; Pradhan S
    Aust N Z J Obstet Gynaecol; 1998 Feb; 38(1):91-2. PubMed ID: 9521401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery.
    Fricker JP; Vergnes Y; Schach R; Heitz A; Eber M; Grunebaum L; Wiesel ML; Kher A; Barbier P; Cazenave JP
    Eur J Clin Invest; 1988 Dec; 18(6):561-7. PubMed ID: 2852111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy.
    Macdonald RL; Amidei C; Lin G; Munshi I; Baron J; Weir BK; Brown F; Erickson RK; Hekmatpanah J
    Neurosurgery; 1999 Aug; 45(2):245-51; discussion 251-2. PubMed ID: 10449068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2199-207. PubMed ID: 10904464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
    McLeod RS; Geerts WH; Sniderman KW; Greenwood C; Gregoire RC; Taylor BM; Silverman RE; Atkinson KG; Burnstein M; Marshall JC; Burul CJ; Anderson DR; Ross T; Wilson SR; Barton P;
    Ann Surg; 2001 Mar; 233(3):438-44. PubMed ID: 11224634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery.
    Sawczuk IS; Williams D; Chang DT
    Cancer Invest; 2002; 20(7-8):889-92. PubMed ID: 12449719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy.
    Macdonald RL; Amidei C; Baron J; Weir B; Brown F; Erickson RK; Hekmatpanah J; Frim D
    Surg Neurol; 2003 May; 59(5):363-72; discussion 372-4. PubMed ID: 12765806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.
    Hartl P; Brücke P; Dienstl E; Vinazzer H
    Thromb Res; 1990 Feb; 57(4):577-84. PubMed ID: 2158151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.
    Hunt BJ; Doughty HA; Majumdar G; Copplestone A; Kerslake S; Buchanan N; Hughes G; Khamashta M
    Thromb Haemost; 1997 Jan; 77(1):39-43. PubMed ID: 9031446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.
    Karthaus M; Kretzschmar A; Kröning H; Biakhov M; Irwin D; Marschner N; Slabber C; Fountzilas G; Garin A; Abecasis NG; Baronius W; Steger GG; Südhoff T; Giorgetti C; Reichardt P
    Ann Oncol; 2006 Feb; 17(2):289-96. PubMed ID: 16317012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
    Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.